Sector: Healthcare | Industry: Biotechnology & Medical Research |
Company Contact | |
Address: | 27 St. Clair Ave E., P.O. Box 305 TORONTO ON M4T 2M5 |
Tel: | 1-647-4287031 |
Website: | https://archbiopartners.com |
IR: | See website |
Key People | ||
Richard Muruve President, Chief Executive Officer, Director | Andrew Bishop Chief Financial Officer, Director | Daniel Muruve Chief Science Officer |
Business Overview |
Arch Biopartners Inc. is a portfolio-based biotechnology company focused on the development of technologies that have the potential to make a medical or commercial impact. The Company is focused on the clinical development of its drug platform in targeting dipeptidase-1 (DPEP-1) mediated organ inflammation in the lungs, liver and kidneys. Its lead drug candidate is LSALT Peptide (Metablok). LSALT Peptide is developed for targeting organ inflammation often experienced in hospitalized COVID-19 patients. It focuses on therapeutic development of LSALT Peptide and other DPEP-1 targeting drug candidates for new indications where inflammation of the lungs, liver and kidneys is an unmet problem. It has additional technology platforms in its portfolio including AB569, which focuses on preventing antibiotic resistant bacterial infections; Borg, which is a peptide-solid surface interface, and MetaMx, which is a synthetic molecule that target brain tumor initiating cells and invasive glioma cells. |
Financial Overview |
For the three months ended 31 December 2023, Arch Biopartners Inc revenues decreased 31% to C$298K. Net loss decreased 64% to C$783K. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects Share based compensation decrease of 70% to C$580K (expense), Research decrease of 70% to C$136K (expense), Insurance decrease of 48% to C$7K (expense). |
Reporting Currency: | Canadian Dollars |
Enterprise value: | $142.25M as of Dec 31, 2023 |
Annual revenue (TTM): | $1.85M as of Dec 31, 2023 |
EBITDA (TTM): | -$1.56M as of Dec 31, 2023 |
Net annual income (TTM): | -$1.95M as of Dec 31, 2023 |
Free cash flow (TTM): | -$0.48M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | $4.73M as of Dec 31, 2023 |
Shares outstanding: | 62,755,633 as of Dec 31, 2023 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |